Weekly Clinical Briefing: The ERAS Evidence Report 1. A New Standard in Perioperative Care The global transition toward Enhanced Recovery After Surgery (ERAS) reflects a strategic pivot to evidence-based protocols established by the ERAS Society. Applied across cardiac, spine, thoracic, and gynecologic specialties, these frameworks standardize care to improve patient trajectories. ERAS adoption is a strategic mandate to replace suboptimal conventional care. This evidence-based shift directly correlates with superior empirical outcomes observed in diverse surgical settings. 2. Metrics of Strategic Success Length of Stay (LOS) and readmission rates are primary indicators of protocol viability. Evidence demonstrates significant impact: gastrectomy cases showed a 3-day LOS reduction, and Alberta’s provincial system reported improved practitioner adherence. ERAS drives substantial cost savings while mitigating perioperative risk through multimodal analgesia. These metrics benchmark high-performing programs by optimizing safety and resource utilization. Consequently, these outcomes necessitate a collaborative multidisciplinary approach. 3. Multidisciplinary Operational Excellence Operational excellence hinges on a core team—nursing, anesthesia, and nutrition. High-value interventions include preoperative carbohydrate loading, prehabilitation, intraoperative Goal-Directed Fluid Therapy, and regional nerve blocks. The ERAS nurse navigator ensures compliance, facilitating accelerated return of gut function and earlier ambulation. High-certainty evidence (IIIA/VA) validates this multidisciplinary model as the definitive standard for surgical recovery.

Limb Reconstruction Surgery in Adults & Pediatrics, taking place 15–18 September 2026 in Egypt. The four-day scientific and educational programme will bring together an international faculty and combine hands-on training, workshops, lectures, symposia and case discussions in limb reconstruction and related disciplines. 🔬 Programme highlights include: •⁠ ⁠15 September – One-Day Microsurgery Training Course on Animal Model, with hands-on micro-neural laboratory training •⁠ ⁠16 September – Sawbones Laboratory •⁠ ⁠17–18 September – Lectures, scientific symposia and clinical case discussions Scientific topics will include internal fixation in deformity, Ilizarov external fixation techniques, diabetic foot and ankle management, and advances in diabetic wound care. A special highlight will be the One-Day Microsurgery Training Course, featuring live microsurgery demonstrations, hands-on training, peripheral nerve exposure and repair, nerve grafting techniques, and microsurgical instrument handling under expert faculty guidance. As shared by Prof. Mohamed Fadel, WAIOT President (2026–2027), it's an opportunity for international participants to visit the Grand Egyptian Museum, Alharam, Egypt alongside the scientific activities. 📅 15–18 September 2026 📍 Egypt For further information write to: a.fath@aicpd.org View the original LRS.PD announcement: https://lnkd.in/eZNAmq3v #WAIOT #LimbReconstruction #Microsurgery #Orthopaedics #Ilizarov #DeformityCorrection #MedicalEducation #OrthopaedicSurgery #InternationalCollaboration

Global Weekly Update: Regenerative Breakthroughs and Evidence Realities in Lumbar Degeneration Disease-modifying interventions must supersede symptomatic management to address proteoglycan depletion. DiscGenics’ IDCT (rebonuputemcel) marks a paradigm shift in structural modification; in June 2026, the DSMB recommended Phase III continuation, reinforcing its unique clinical profile. Clinical Differentiators: - Structural Regeneration: MRI-confirmed disc volume increase (402.1 mm³ at 104 weeks). - Functional Durability: Significant, sustained improvements in pain and quality of life exceeding the MCID. - Dose-Dependent Efficacy: Only the high-dose group demonstrated a decrease in both opioid and NSAID usage. While progenitors show promise, traditional MSC applications were confounded by the hostile disc microenvironment—hypoxia, acidity, and nutrient deprivation. Recent landmark RCTs, including the RESPINE study and the Mesoblast Phase III trial, failed primary endpoints despite excellent safety. This disconnect stems from 70% placebo response rates—making it difficult to power for the modest effects present—and poor cell survival (under 10% in degenerated discs 48 hours post-injection). We must cease the conflation of safety and efficacy. The Kume et al. Three-Tier Framework reveals that Tier 1 remains empty because no product has demonstrated superiority over active comparators (e.g., corticosteroids), only inert placebos. While the aggregate class-level benefit (Hedges g) is robust, it lacks structural confirmation. Strategically, the field is pivoting toward cell-free modalities like Platelet Lysate and Extracellular Vesicles. These offer batch-controlled scalability and bypass survival constraints, providing a more reliable clinical outlook for precision orthopedic practice.

Hi collegues there is a new learning tool,a place to find all videos about general orthopedics: Maestro Ortopedia